Last reviewed · How we verify

SP IPT

Institute of Tropical Medicine, Belgium · Phase 3 active Small molecule

SP IPT is a vaccine that targets the SARS-CoV-2 spike protein.

SP IPT is a vaccine that targets the SARS-CoV-2 spike protein. Used for COVID-19 prevention.

At a glance

Generic nameSP IPT
Also known asSP, Fansidar (R)
SponsorInstitute of Tropical Medicine, Belgium
Drug classvaccine
TargetSARS-CoV-2 spike protein
ModalitySmall molecule
Therapeutic areaInfectious Disease
PhasePhase 3

Mechanism of action

The vaccine works by inducing an immune response against the spike protein, which is a key component of the SARS-CoV-2 virus. This immune response helps to prevent infection and reduce the severity of COVID-19 symptoms.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: